Starpharma

Gain a direct line to Starpharma's leadership


Be first to know our latest company updates


Watch exclusive videos accompanying major
news

Home

Our Brands

Team

Research Publications

Our Capabilities

About Starpharma

Company

DEP® Drug Delivery Platform

Dendrimer Technology

DEP® Solutions

Pipeline & Products

Corporate Governance

Shareholder Services

Stock Listing

Market Data

Annual General Meeting 2025

Annual Reports

Video Library

Investor Presentations

Updates

ASX Announcements

Why Invest

Announcements

Careers

Our People & Culture

People & Culture

Star Navigator

Starpharma Partnerships

Partnerships

Poppins

Starpharma (ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology. 

Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties - including their size, structure, high degree of branching, polyvalency, and water solubility - are advantageous in medical and pharmaceutical applications. 

Starpharma's portfolio of dendrimer-based products includes three clinical-stage DEP® (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products. 

Speaker: Cheryl Maley, CEO & Managing Director  

This was recorded at our Ignite Investment Summit from 26-27 March 2025.

Ignite Investment Summit, Hong Kong, March 2025